Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD)

Data to be presented at the 2023 International Society of Neurochemistry (ISN) and the European Society of Neurochemistry (ESN) meeting in Portugal Data provides further evidence that selective neuronal nitric oxide synthase (nNOS) inhibitors can play a role in the treatment of ASD Poster presentation position nitric oxide (NO) as a novel therapeutic target for ASD: Focus on CNTNAP2-/- mouse model GARDEN CITY, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air”

Related Keywords

Portugal ,Hebrew University ,Yerushalayim ,Israel ,Boston ,Massachusetts ,United States ,Jerusalem ,Israel General ,Americans ,Edward Barger ,Steve Lisi ,Haitham Amal ,Corey Davis ,Tel Aviv University ,Exchange Commission ,Hebrew University Of Jerusalem ,Novartis ,Institute For Drug Research ,Research Development Company Of The Hebrew University ,Nasdaq ,Lifesci Advisors ,Boston Scientific ,European Society Of Neurochemistry ,Hebrew University Of Jerusalem Is Israel ,Amal Lab ,School Of Pharmacy ,Cancer Ltd ,Johnson ,Hebrew University Of Jeruselam ,Intel ,International Society Of Neurochemistry ,European Society ,Beyond Cancer ,Autism Spectrum Disorder ,Annual International Society ,Chief Executive Officer ,Beyond Air ,Research Development Company ,Assistant Professor ,Nobel Prizes ,Drug Research ,Molecular Psychiatry ,Autism Spectrum ,Annual Report ,Sci Advisors ,Neurological Disorders ,Iopharmaceutical Company ,Faculty Of Medicine ,Preclinical Data ,Nitric Oxide ,